SCHEMBL2194402

SCHEMBL2194402

C[C@]1(O)CC[C@@H](NS(=O)(=O)c2ccc(Br)cc2)CC1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.63
HTT P42858 1/20 0.63
APP P05067 1/20 0.53
SMN1; SMN2 Q16637 3/20 0.51
KDM4E B2RXH2 1/20 0.51
RECQL P46063 1/20 0.51
ALDH1A1 P00352 7/20 0.48
CYP3A4 P08684 1/20 0.48
TSHR P16473 1/20 0.48
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
HSP90AA1 P07900 1/20 0.46
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
MMP1 P03956 1/20 0.45
MMP2 P08253 1/20 0.45
MMP9 P14780 1/20 0.45
MMP8 P22894 1/20 0.45
MMP13 P45452 1/20 0.45
LMNA P02545 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2194405 1.00 MAPK1 (0.63) MAPK1HTTAPPSMN1; SMN2KDM4E
SCHEMBL2194407 1.00 MAPK1 (0.63) MAPK1HTTAPPSMN1; SMN2KDM4E
SCHEMBL23953194 0.85 APP (0.53) APPSMN1; SMN2KDM4ERECQLALDH1A1
SCHEMBL1723430 0.83 UCHL1 (0.50) SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4
SCHEMBL16335707 0.83 UCHL1 (0.50) SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4
SCHEMBL19994813 0.82 ALDH1A1 (0.53) MAPK1HTTSMN1; SMN2KDM4ERECQL
SCHEMBL1659340 0.82 MAPK1 (0.83) MAPK1HTTSMN1; SMN2KDM4ERECQL
SCHEMBL19667871 0.81 MAPK1 (0.46) MAPK1HTTSMN1; SMN2KDM4ERECQL
SCHEMBL17847655 0.81 MAPK1 (0.46) MAPK1HTTSMN1; SMN2KDM4ERECQL
SCHEMBL16378516 0.81 KMT2A (0.55) MAPK1HTTSMN1; SMN2KDM4ERECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3262028-B1 N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-PHENYL-BENZENESULFONAMIDE AND N-(-4HYDROXY-4-METHYL-CYCLOHEXYL)-4-(2-PYRIDYL)-BENZENESULFONAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE PIMCO 2664 LTD (GB) 2021-10-27 EP disclosed
CN-107108508-B N- (4-hydroxy-4-methyl-cyclohexyl) -4-phenyl-benzenesulfonamide and N- (4-hydroxy-4-methyl-cyclohexyl) -4- (2-pyridyl) -benzenesulfonamide compounds and their therapeutic use 皮姆科2664有限公司 2020-09-01 CN disclosed
US-10233147-B2 N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use PIMCO 2664 LIMITED (GB) 2019-03-19 US disclosed
US-20180319742-A1 N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-PHENYL-BENZENESULFONAMIDES AND N-(4- HYDROXY-4-METHYL-CYCLOHEXYL)-4-(2-PYRIDYL)BENZENESULFONAMIDES AND THEIR THERAPEUTIC USE PIMCO 2664 LIMITED (GB) 2018-11-08 US disclosed
US-20180297955-A1 N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-PHENYL-BENZENESULFONAMIDE AND N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-(2-PYRIDYL)-BENZENESULFONAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE PIMCO 2664 LIMITED (GB) 2018-10-18 US disclosed
US-10029979-B2 N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use PIMCO 2664 LIMITED (GB) 2018-07-24 US disclosed
US-10005733-B2 N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use PIMCO 2664 LIMITED (GB) 2018-06-26 US disclosed
US-10005733-B2 N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use PIMCO 2664 LIMITED (GB) 2018-06-26 US disclosed
US-10005733-B2 N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use PIMCO 2664 LIMITED (GB) 2018-06-26 US disclosed
US-20180037544-A1 N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-PHENYL-BENZENESULFONAMIDES AND N-(4- HYDROXY-4-METHYL-CYCLOHEXYL)-4-(2-PYRIDYL)BENZENESULFONAMIDES AND THEIR THERAPEUTIC USE PIMCO 2664 LIMITED (GB) 2018-02-08 US disclosed
US-20160145206-A1 N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-PHENYL-BENZENESULFONAMIDES AND N-(4- HYDROXY-4-METHYL-CYCLOHEXYL)-4-(2-PYRIDYL)BENZENESULFONAMIDES AND THEIR THERAPEUTIC USE PIMCO 2664 LIMITED (GB) 2016-05-26 US disclosed
US-9302984-B2 Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use PIMCO 2664 LIMITED (GB) 2016-04-05 US disclosed
US-20150266815-A1 Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use PIMCO 2664 LIMITED (GB) 2015-09-24 US disclosed
US-9050329-B1 Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use PIMCO 2664 LIMITED (GB) 2015-06-09 US disclosed
US-20150141472-A1 Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use PIMCO 2664 LIMITED (GB) 2015-05-21 US disclosed
EP-2344449-B1 ARYL-PHENYL-SULFONAMIDO-CYCLOALKYL COMPOUNDS AND THEIR USE PIMCO 2664 LTD (GB) 2015-05-13 EP disclosed
US-8822507-B2 Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use PIMCO 2664 LIMITED (GB) 2014-09-02 US disclosed
US-20130245018-A1 Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use PIMCO 2664 LIMITED (US) 2013-09-19 US disclosed
US-8435968-B2 Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use PIMCO 2664 LIMITED (GB) 2013-05-07 US disclosed
US-20110172189-A1 Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use PIMCO 2664 LIMITED (GB) 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172189-A1 Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use SOST, AADAC, ARSA MAPK1 1950/4885HTT 2591/4885APP 432/4885
US-20180037544-A1 N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-PHENYL-BENZENESULFONAMIDES AND N-(4- HYDROXY-4-METHYL-CYCLOHEXYL)-4-(2-PYRIDYL)BENZENESULFONAMIDES AND THEIR THERAPEUTIC USE BRCA1, TPMT, SOST MAPK1 2198/4885HTT 624/4885APP 1696/4885
US-10029979-B2 N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use BRCA1, TPMT, SOST MAPK1 2218/4885HTT 592/4885APP 1701/4885
US-20150141472-A1 Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use SOST, AADAC, ARSA MAPK1 1918/4885HTT 2680/4885APP 438/4885
US-20180297955-A1 N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-PHENYL-BENZENESULFONAMIDE AND N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-(2-PYRIDYL)-BENZENESULFONAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE BRCA1, MYLK2, SOST MAPK1 2040/4885HTT 532/4885APP 1787/4885
US-20130245018-A1 Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use SOST, AADAC, ARSA MAPK1 1918/4885HTT 2680/4885APP 438/4885
US-20150266815-A1 Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use SOST, AADAC, ARSA MAPK1 1918/4885HTT 2680/4885APP 438/4885
US-20160145206-A1 N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-PHENYL-BENZENESULFONAMIDES AND N-(4- HYDROXY-4-METHYL-CYCLOHEXYL)-4-(2-PYRIDYL)BENZENESULFONAMIDES AND THEIR THERAPEUTIC USE BRCA1, TPMT, SOST MAPK1 2198/4885HTT 624/4885APP 1696/4885
US-10233147-B2 N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use BRCA1, TPMT, SOST MAPK1 2218/4885HTT 592/4885APP 1701/4885
US-10005733-B2 N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use BRCA1, MYLK2, SOST MAPK1 2073/4885HTT 528/4885APP 1794/4885
US-20180319742-A1 N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-PHENYL-BENZENESULFONAMIDES AND N-(4- HYDROXY-4-METHYL-CYCLOHEXYL)-4-(2-PYRIDYL)BENZENESULFONAMIDES AND THEIR THERAPEUTIC USE BRCA1, TPMT, SOST MAPK1 2198/4885HTT 624/4885APP 1696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.